JH
Jason Haas (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $2.1M of LGND (7,138 sh × $292.81, as filed), executed Aug 12. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$3.7M
shares × price, as filed
Last traded
Aug 12
Filed Aug 14
Median ADV $104.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $3.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
LGNDRecent filings
LGNDSALE
Ligand Pharmaceuticals Incorporated
View filing →
$2.1M7,138 sh × $292.81
Exec Aug 12
Filed Aug 14 · 5:04 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $1.7M
6,461 sh across 2 lots
Exec Jun 12
Filed Jun 15 · 5:30 PM ET